Superficial tumors are the most frequent of ... or intermediate-term follow-up of superficial bladder cancer. Tumor size, multiplicity, CIS and tumor stage and grade are listed as clinical and ...

The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive ...

Including transurethral resection of bladder tumors, induction chemotherapy, followed by concurrent radiochemotherapy, assessment cystoscopy and consolidation radiochemotherapy. Cis: Cisplatin ...

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product ...

in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).

ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit ImmunityBio.com (Founder’s ...

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA ® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS ...